Corrigendum to 'Co-delivery paclitaxel and IR783 as nanoparticles for potentiated chemo-photothermal-immunotherapy of triple-negative breast cancer' [Mater. Today Bio <b>33</b> (2025) 101993]. [PDF]
Mater Today BioHuang Y +9 more
europepmc +1 more source
Asia-Pacific Journal of Clinical Oncology, EarlyView.This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott +8 more
wiley +1 more source
Relative Clinical Efficacy and Safety of Second- or Later-Line Treatments for Advanced and Metastatic Gastric Cancer: A Rapid Review and Network Meta-Analysis. [PDF]
J Gastrointest CancerSharma S +7 more
europepmc +1 more source
Targeting the c-Met/VEGFR Pathway to Boost <i>Nab</i>-Paclitaxel Efficacy in Gastric Cancer: Preclinical Insights. [PDF]
CellsHuang J +4 more
europepmc +1 more source
The ups and downs of paclitaxel-coated balloons and paclitaxel eluting stents: do the conclusions of SWEDEPAD 2 change our practice? Should we be concerned about mortality (again)? [PDF]
CVIR EndovascMüller-Hülsbeck S +11 more
europepmc +1 more source
Paclitaxel compromises nuclear integrity in interphase through SUN2-mediated cytoskeletal coupling. [PDF]
J Cell SciHale T +4 more
europepmc +1 more source
Top 5 Advances in the Last 50 Years: Malignant Gastric and Esophageal Surgery
World Journal of Surgery, EarlyView.
Luís Santos Castro, Lorenzo Ferri
wiley +1 more source
Adaptations in Plasmodium tubulin determine distinct microtubule architectures, mechanics and drug susceptibility. [PDF]
Nat CommunBangera M +7 more
europepmc +1 more source
Pancreatic Cancer—Advances in the Last 50 Years
World Journal of Surgery, EarlyView.
S. George Barreto +5 more
wiley +1 more source